Evaluation of Posterior Capsule Opacification in Eyes With Diabetes Mellitus (DM & PCO)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Iladevi Cataract and IOL Research Center
ClinicalTrials.gov Identifier:
NCT01480934
First received: November 24, 2011
Last updated: November 28, 2011
Last verified: November 2011
  Purpose

To compare the development of posterior capsule opacification (PCO) between eyes with and without a history of diabetes mellitus (DM) after single-piece hydrophobic acrylic intraocular lens (IOL) implantation 4 years postoperatively.Diabetes mellitus would not increase the incidence of PCO at 4 years.


Condition
Development of Posterior Capsule Opacification

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: A Prospective Evaluation of Posterior Capsule Opacification in Eyes With Diabetes Mellitus -A Case Control Study

Resource links provided by NLM:


Further study details as provided by Iladevi Cataract and IOL Research Center:

Primary Outcome Measures:
  • Development of Posterior capsule opacification. [ Time Frame: 4 years ] [ Designated as safety issue: No ]
    This prospective, observational case control study comprised patients who underwent phacoemulsification .Subjects with a history of diabetes mellitus (DM) were designated as cases (n=75 eyes).Inclusion criteria for cases: Diabetes mellitus was defined as glycosylated haemoglobin (Hb A1c ) levels of 6% or more , use of diabetic medication (oral hypoglycemic agents, insulin injection or diet restriction), or a physician's diagnosis of diabetes. Patients with uncomplicated age-related cataract who were otherwise healthy constituted the controls (n=75 eyes).


Secondary Outcome Measures:
  • duration of diabetes, stage of diabetic retinopathy [ Time Frame: 4 years ] [ Designated as safety issue: No ]
    The stage of diabetic retinopathy and duration of diabetes was correlated with the degree of PCO in the cases group.


Enrollment: 150
Study Start Date: June 2005
Study Completion Date: June 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
Group:A-cases-Patients with a history of Diabetes Mellitus
(N=75 eyes). The inclusion criteria for group A: Diabetes mellitus was defined as glycosylated haemoglobin (Hb A1c ) levels of 6% or more , use of diabetic medication (oral hypoglycemic agents, insulin injection or diet restriction), or a physician's diagnosis of diabetes.
Group - B:controls
Patients with uncomplicated age-related cataract who were otherwise healthy constituted the controls(Group:)B (n=75 eyes).

Detailed Description:

There is a paucity of available literature that prospectively evaluates the development of PCO with the single-piece hydrophobic acrylic IOL implantation in diabetic versus non-diabetic eyes on a long-term basis. Therefore, this study was designed to compare the degree of PCO after cataract surgery between diabetic and age-matched non-diabetic patients. This prospective, observational case control study comprised patients who underwent phacoemulsification .The patients were asked to return for postoperative follow-up visits at 1 month, 1 year and 4 years.

the digital images were analyzed for PCO .

  Eligibility

Ages Eligible for Study:   50 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

patients who underwent phacoemulsification for age-related cataract

Criteria

Inclusion Criteria:

  • Diabetes mellitus was defined as glycosylated haemoglobin (Hb A1c ) levels of 6% or more ,
  • use of diabetic medication (oral hypoglycemic agents, insulin injection or diet restriction), or a physician's diagnosis of diabetes.
  • Patients with uncomplicated age-related cataract who were otherwise healthy constituted the controls (n=75 eyes).

Exclusion Criteria:

  • patients with glaucoma,
  • high myopia (axial length > 27.0 mm),
  • pseudoexfoliation,
  • traumatic cataract,
  • subluxated cataract,
  • previous ocular surgeries,
  • allergy to dilating drops.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01480934

Sponsors and Collaborators
Iladevi Cataract and IOL Research Center
Investigators
Principal Investigator: Gauri D Shah, M.S Iladevi Cataract &IOL Research Centre
  More Information

No publications provided

Responsible Party: Iladevi Cataract and IOL Research Center
ClinicalTrials.gov Identifier: NCT01480934     History of Changes
Other Study ID Numbers: 01072007
Study First Received: November 24, 2011
Last Updated: November 28, 2011
Health Authority: India: Institutional Review Board

Keywords provided by Iladevi Cataract and IOL Research Center:
Diabetes,posterior capsule opacification,case control study

Additional relevant MeSH terms:
Capsule Opacification
Diabetes Mellitus
Cataract
Endocrine System Diseases
Eye Diseases
Glucose Metabolism Disorders
Lens Diseases
Metabolic Diseases

ClinicalTrials.gov processed this record on October 23, 2014